BioAge Announces Groundbreaking Obesity Treatment Trial
BioAge Labs has initiated a Phase 2 clinical trial, STRIDES, to assess the efficacy of azelaprag, a small molecule...
Venetoclax and Fixed-Duration Calquence® Significantly Improve Leukemia Survival
An interim analysis of the AMPLIFY Phase III trial has revealed encouraging results in the treatment of chronic lymphocytic...
Seqster’s Digital Health Technology: Unveiling a Revolutionary Alzheimer’s Screening Breakthrough
SEQSTER PDM Inc. and Boston University researchers, led by Dr. Rhoda Au, have partnered to develop an innovative early...
FDA on The Exciting Future of Clinical Trial Regulatory Affairs
The 2024 DIA conference hosted a session, Regulatory Affairs of the Future is Now, which was a dynamic and...
Aditxt Inks Agreement with Appili, Aiming for September Acquisition
Appili Therapeutics, a biopharmaceutical company specializing in infectious disease treatments and vaccines, has secured CAD $100 million in funding...
Viridian Therapeutics Announces: Thrive-2 Enrollment Complete for Ted Patients
Viridian Therapeutics announced the completion of enrollment in its phase 3 clinical trials, THRIVE and THRIVE-2, targeting patients with...
FDA Approves Mirum’s Livmarli for PFIC in 12-Month-Olds and Up
Mirum Pharmaceuticals has received FDA approval to expand the use of LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus...
Schrödinger Launches Breakthrough Initiative to Advance Predictive Toxicology with Computational Tools
Schrödinger, Inc. has embarked on an initiative to enhance its computational platform for early predicting toxicology risk in drug...
Merck’s Keytruda and Padcev Combo Receives EU Recommendation for Unresectable Urothelial Carcinoma
The European Medicines Agency (EMA) has recommended approval of Merck’s KEYTRUDA and Padcev combination for the first-line treatment of...
LEO Pharma Receives Positive CHMP Opinion for Anzupgo® for Moderate to Severe Chronic Hand Eczema
LEO Pharma, a leading dermatology company, announced a positive opinion from the European Medicines Agency (EMA) for Anzupgo® (delgocitinib...